Articles

Pascal Degen, Vice President of Global Supply Chain Management at Bachem, explains the challenges faced by the CDMOs in a VUCA world
Pharmaceutical supply chains are becoming increasingly vulnerable to a range of disruptions. From geopolitical upheavals to natural disasters, the unpredictability of the modern world demands innovative strategies for maintaining stability in the face of disruption.  Contract Development and Manufacturing Organizations (CDMOs) play a critical role in navigating these challenges by ensuring the consistent production and delivery of life-saving medications. There is a pressing need for CDMOs to address these supply chain challenges in a volatile, uncertain, complex, and ambiguous (VUCA) environment, and to implement strategies for resilience in the face o…

The global large bore vascular closure device market is witnessing rapid growth, driven by the increasing demand for effective medical solutions to address large puncture sites in arteries following catheter-based surgeries.
Introduction to the Large Bore Vascular Closure Device Market The global large bore vascular closure device market is a dynamic and rapidly evolving segment of the medical device industry, primarily driven by the increasing prevalence of cardiovascular diseases, advancements in medical technology, and the growing demand for minimally invasive procedures. Large bore vascular closure devices are specialized medical tools used to close large puncture sites in blood vessels, typically resulting from catheter insertions during complex procedures like endovascular surgeries a…

Up to now, the pharma industry’s advances in implementing ISO IDMP product data standards have been patchy. New research has looked more closely at companies’ IDMP readiness, as well as their progress with FAIR data principles and plans to adopt Pistoia Alliance’s IDMP-Ontology. MAIN5’s Michiel Stam discusses the findings.
With renewed momentum around ISO IDMP internationally, MAIN5 recently partnered with Pistoia Alliance and data registry specialist Accurids to determine current progress toward IDMP implementation. The benchmark study[1] also explored companies’ relative maturity in supporting FAIR data principles, geared to making data more Findable, Accessible, Interoperable, and Reusable. These are championed by Pistoia Alliance, whose IDMP-Ontology (IDMP-O) project aims to encourage u…

Especially in recent years, Artificial Intelligence (AI) has emerged as a transformative force across industries, and the pharmaceutical sector is no exception. One of the key areas where AI is having a significant impact is in Quality Assurance (QA). Ensuring the safety, efficacy, and quality of pharmaceutical products is paramount, and AI technologies have the power to revolutionise these processes.
Especially in recent years, Artificial Intelligence (AI) has emerged as a transformative force across industries, and the pharmaceutical sector is no exception. One of the key areas where AI is having a significant impact is in Quality Assurance (QA). Ensuring the safety, efficacy, and quality of pharmaceutical products is paramount, and AI technologies have the power to revolutionise these pr…

AI has proven beneficial in the pharmaceutical cold chain by improving the efficacy and safety of temperature-controlled medication. Specifically, AI has helped with real-time temperature monitoring, demand forecasting, quality control, and more.
The health care and pharmaceutical industries have undergone impressive developments in recent years with the rise of artificial intelligence (AI). Cold chains, in particular, have benefited from these new technologies, improving the efficacy and safety of temperature-controlled medication.  The Importance of AI in Pharma Cold Chains Cold-chain pharmaceuticals comprise drugs, vaccines, active ingredients and biological substances requiring specialized thermal packaging solutions from production to distribution. The increasing popularity of cel…

Coulter Partners' recent top global hires for large-cap, mid-cap, and public companies, covered a broad range of disciplines and sectors across Life Sciences, Health and Tech in the second half of 2024.
  CEO/ C-suite/ Board Function Focus area Location CEO Medtech (publicly listed) APAC CEO Life science tools (publicly listed) Nordics President Life Sciences Specialty chemicals (large-cap) UK & Ireland Chief Financial Officer Biotech (publicly listed) US Chief Financial Officer Biopharma/ drug delivery (publicly listed) UK & Ireland Chief of Staff Biopharma (publicly listed) Europe Chair Mental health pharma (publicly listed) US/ UK       Commercial / Functional / Strategic Leadership …

“The NHS is in a critical condition, but its vital signs are strong” were words captured in Lord Darzi’s recent independent investigation of the National Health Service England . With waiting times for hospital procedures continuing to surge, treatment targets are being missed and this is having a negative impact on patient outcomes – and the health of the nation as a whole.
“The NHS is in a critical condition, but its vital signs are strong” were words captured in Lord Darzi’s recent independent investigation of the National Health Service England[1]. With waiting times for hospital procedures continuing to surge, treatment targets are being missed and this is having a negative impact on patient outcomes – and the health of the nation as a whole. According to figures gathered by the report…

tiakis Biotech AG today announced the results of its randomized, double-blind, placebo-controlled clinical Phase Ib/II COMCOVID trial evaluating Tiprelestat for the treatment of patients hospitalized due to COVID-19. Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy.
Kiel, Germany, December 9, 2024 – tiakis Biotech AG, a clinical-stage biopharmaceutical company developing novel therapeutics for life-threatening pulmonary and cardiovascular diseases, today announced the results of its randomized, double-blind, placebo-controlled clinical Phase Ib/II COMCOVID trial evaluating Tiprelestat for the treatment of patients hospitalized due to COVID-19. In 2021, tiakis Biotech received support from the German Federal Ministry of Education and Research (“BMBF”) to initi…

Next-generation sequencing (NGS) has revolutionized the field of genomics by enabling researchers to generate vast amounts of sequence data in a single experiment. This technology is particularly valuable in applications such as metagenomics, where it allows for the analysis of complex microbial communities, such as those found in the human gut.
Next-generation sequencing (NGS) has revolutionized the field of genomics by enabling researchers to generate vast amounts of sequence data in a single experiment. This technology is particularly valuable in applications such as metagenomics, where it allows for the analysis of complex microbial communities, such as those found in the human gut. However, despite its advantages, NGS is not without its challenges. The quality of the raw sequencing da…

This explosion of information presents both remarkable opportunities and significant challenges for researchers. In this era of big data, bioinformatics has emerged as a crucial field, making substantial strides in the analysis and interpretation of complex biological datasets. As a result, there is a pressing need for the development of sophisticated computational techniques and tools that facilitate effective data analysis and visualization, ultimately enhancing our understanding of intricate biological processes.
The advent of next-generation sequencing (NGS) technologies and advanced sequencers has led to an unprecedented surge in biological data generated by the scientific community. This explosion of information presents both remarkable opportunities and significant challenges for res…

Illumina sequencing, a hallmark of second-generation sequencing technology, has revolutionized genomics research. This method employs a sophisticated reversible dye terminator technology to accurately determine the sequence of DNA molecules. The process begins with the fragmentation of DNA samples into short segments, typically ranging from 100 to 150 base pairs (bp).
In the rapidly evolving field of genomics, sequencing technologies play a crucial role in advancing our understanding of genetic material. Among the most prominent methods are Illumina sequencing and nanopore sequencing, each offering unique advantages and capabilities that cater to different research needs.   What is Illumina Sequencing? Illumina sequencing, a hallmark of second-generation sequencing technology, has revo…

The significance of degradome sequencing lies in its ability to provide a more accurate and reliable identification of miRNA target genes compared to traditional bioinformatics predictions. By directly analyzing mRNA degradation fragments, researchers can validate miRNA interactions with target genes more effectively, thus simplifying subsequent experimental validation.
Degradome sequencing, also known as parallel analysis of RNA ends (PARE) sequencing, is a cutting-edge technique that leverages high-throughput sequencing and bioinformatics to investigate the degradation products of mRNA. This method is particularly valuable for identifying the target genes regulated by microRNAs (miRNAs), which are small, endogenous non-coding RNAs approximately 22 nucleotides in length. miRNAs play crucia…

Traditional RNA sequencing methods typically analyze bulk samples containing thousands to millions of cells, which can obscure the unique characteristics of individual cells. Since the pioneering scRNA-seq study in 2009, there has been a surge of interest and research in this field, primarily driven by specialized laboratories equipped with advanced wet-lab techniques, bioinformatics expertise, and computational resources.
Introduction to Single-Cell RNA Sequencing Single-cell RNA sequencing (scRNA-seq) represents a groundbreaking advancement in genomic techniques, allowing researchers to detect and quantify messenger RNA (mRNA) molecules at the single-cell level. This capability is crucial for understanding cellular responses and the intricate dynamics of biological systems. Traditional RN…

Pharma Contract Manufacturing 2025 is taking place in Berlin next March (26-27th) Ahead of our conference, we spoke to partners at Fuliginous Management Consulting to gain expert insights into building effective pricing models for CDMO partnerships.
Pharma Contract Manufacturing 2025 is taking place in Berlin next March (26-27th). Download the event details here: https://shorturl.at/p4iFE Ahead of our conference, we spoke to partners at Fuliginous Management Consulting to gain expert insights into building effective pricing models for CDMO partnerships. The exclusive interview with Kyriakos Kansos and George Ntortas explores essential strategies for tackling pricing complexities including adopting value-based approaches and designing risk-sharing agreements that enhance profitability whil…

The Sports Medicine Devices Market Size was valued at USD 7.3 Billion in 2022 and is projected to reach USD 14.3 Billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.
The Sports Medicine Devices Market is experiencing robust growth, driven by increasing participation in sports, rising awareness of physical fitness, and advancements in medical technologies. In 2022, the market was valued at USD 7.3 billion, and it is projected to nearly double to USD 14.3 billion by 2032, with a healthy CAGR of 7.1% from 2023 to 2032. This article delves into the competitive landscape, market drivers and restraints, growth opportunities, regional insights, and current trends shaping the future of this dynamic industry. Download Free Sports Medicine Devices Market Sample Report Here: (Including Full T…

The Vessel Sealing Devices Market Size was valued at USD 1.9 Billion in 2022 and is expected to reach USD 3.5 Billion by 2032, growing at a CAGR of 6.7% from 2023 to 2032.
The Vessel Sealing Devices Market is experiencing notable growth, driven by advancements in surgical technologies and increasing global demand for minimally invasive procedures. Valued at USD 1.9 billion in 2022, the market is projected to reach USD 3.5 billion by 2032, growing at a robust CAGR of 6.7% from 2023 to 2032. This article explores the market’s competitive landscape, growth opportunities, key drivers, restraints, major players, trends, and regional insights. Download Free Vessel Sealing Devices Market Sample Report Here: (Including Full TOC, List of Tables & Figures, Chart) https://www.acumenresearchandcons…

The Vital Signs Monitoring Devices Market Size was valued at USD 8.9 Billion in 2022 and is projected to reach USD 16.9 Billion by 2032, with a compound annual growth rate CAGR of 6.8% during the forecast period from 2023 to 2032.
The Vital Signs Monitoring Devices Market is witnessing significant growth, driven by the increasing demand for real-time health monitoring and the growing prevalence of chronic diseases. Valued at USD 8.9 billion in 2022, this market is expected to achieve a size of USD 16.9 billion by 2032, growing at a CAGR of 6.8% from 2023 to 2032. In this article, we delve into the market's competitive landscape, growth prospects, drivers, restraints, leading players, current trends, and regional dynamics. Download Free Vital Signs Monitoring Devices Market Sample Report Her…

Explore how a healthcare app development company delivers secure and innovative healthcare app development services to enhance patient care and efficiency.
A<a href="https://www.jploft.com/healthcare-app-development">Healthcare App Development Company</a> specializes in creating advanced, secure, and user-friendly digital solutions for the healthcare industry. By offering comprehensive Healthcare App Development Services, these companies design applications for telemedicine, patient management, appointment scheduling, fitness tracking, and more. Their solutions ensure seamless communication between patients and providers while adhering to strict regulatory standards like HIPAA and GDPR. With expertise in leveraging cutting-edge technologies such as AI, IoT, and blockchain, these…

The Dental Digital X-Ray Market Size was valued at USD 3.7 Billion in 2022 and is projected to reach USD 9.3 Billion by 2032, registering a CAGR of 9.8% during the period from 2023 to 2032.
The Dental Digital X-Ray Market, valued at USD 3.7 billion in 2022, is projected to surge to a remarkable USD 9.3 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.8% from 2023 to 2032. This substantial growth underscores the pivotal role of digital X-ray technology in revolutionizing dentistry, driven by advancements in healthcare infrastructure, increasing awareness about oral health, and a growing aging population. This article explores the competitive landscape, future growth prospects, key opportunities, challenges, drivers, restraints, current trends, major market players, and…

Scientific breakthroughs are the catalyst to developing new treatments for diseases. From the rapid development of COVID-19 vaccines to a single-dose breast cancer treatment, novel science has been central. After releasing its novelty scores feature, DeSci Labs has enabled the public to compare the novelty scores of more than 250 million articles in the scientific literature. Here, Philipp Koellinger, co-founder and CEO, explains what the novelty scores are, and the effect they can have on the pharmaceutical sector.
Scientific breakthroughs are the catalyst to developing new treatments for diseases. From the rapid development of COVID-19 vaccines to a single-dose breast cancer treatment, novel science has been central. After releasing its novelty scores feature, DeSci Labs has enabled the p…